Condition: Kidney Transplant Recipients · Old Age · Sponsor: Massachusetts General Hospital
The objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (IR) tacrolimus (Prograf®) and those who were converted to extended-release tacrolimus (Envarsus XR) among older kidney transplant recipients (KTRs).
This description comes directly from the study's public registry record.
Leonardo V. Riella, MD, PhD · 6177240345 · lriella@mgh.harvard.edu
Amelia Stocking · 617-724-1976 · astocking@mgh.harvard.edu
Always discuss trial participation with your own doctor first.
| MGH Kidney Transplant Clinic | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06751992